CG Oncology Inc. (CGON) Balance Sheet

The balance sheet has expanded significantly, but this growth is primarily attributable to capital raises rather than operational performance. Retained earnings have deteriorated from -$146.9M to -$518.2M over the period, reflecting escalating R&D and SG&A costs. The trajectory suggests that while the company has ample liquidity, its net asset position is being eroded by ongoing losses, and future dilution may be necessary to sustain operations.

The low leverage is a positive, but it reflects a pre-revenue stage where debt is not yet accessible. The company's cash burn is substantial relative to its cash position, and with no revenue to service debt, any future borrowing would likely be dilutive or carry high costs. The absence of debt provides flexibility, but it also means the company must rely on equity markets, which could be challenging in a risk-off environment.

The asset base is dominated by cash and short-term investments, consistent with a clinical-stage biotech. The appearance of goodwill and intangibles in 2025Q3, after being zero in prior quarters, likely reflects a business combination or in-licensing deal. While the amounts are small relative to total assets, they introduce potential impairment charges if clinical programs underperform. The low PPE underscores the asset-light nature, but the growing intangibles warrant monitoring for future write-downs.

The equity base is largely composed of paid-in capital from IPO and follow-on offerings, not retained earnings. The cumulative deficit is growing rapidly, and SBC is a significant non-cash expense that dilutes existing shareholders. While the current equity cushion provides a buffer, the trend suggests that without a successful commercial launch, the company will continue to consume equity value, potentially leading to further dilution or a need for restructuring.

The current ratio is misleadingly strong because it is driven by a large cash balance relative to current liabilities, but the absolute cash position is declining sharply. The company's burn rate, as evidenced by operating losses, far exceeds its cash reserves, indicating an imminent need for additional financing. The high current ratio provides little comfort if the company cannot access capital markets, and the rapid cash depletion suggests a high risk of dilution or distress.